RecruitingPHASE1, PHASE2NCT07282847
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)
Studying Glycogen storage disease due to acid maltase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AskBio Inc
- Intervention
- AB-1009 (GAA Gene)(genetic)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2032
Study locations (10)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- University of California, Irvine (UCI), Irvine, California, United States
- Stanford Neuroscience Health Center, Palo Alto, California, United States
- NYU Langone, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Oregon Health and Science University (OHSU), Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
- University of Texas Southwest Medical Center, Dallas, Texas, United States
- Virginia Commonwealth University (VCU), Richmond, Virginia, United States
Collaborators
Bayer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07282847 on ClinicalTrials.govOther trials for Glycogen storage disease due to acid maltase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseUniversity of Missouri-Columbia
- RECRUITINGPHASE2NCT07123155Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)Shionogi
- RECRUITINGPHASE4NCT06666413China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDGenzyme, a Sanofi Company
- RECRUITINGNCT06795152Rare Glycogen Storage Diseases Natural History StudyDuke University
- RECRUITINGPHASE1, PHASE2NCT06391736Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy DrugGeneCradle Inc
- RECRUITINGNCT06121011A Global Prospective Observational Registry of Patients With Pompe DiseaseAmicus Therapeutics
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06109948Study to Assess the Safety, Tolerability, PK and PD of ABX1100Aro Biotherapeutics
- ACTIVE NOT RECRUITINGNCT05943678Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.Medical University of Vienna
See all trials for Glycogen storage disease due to acid maltase deficiency →